[go: up one dir, main page]

EP2571361A4 - PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER - Google Patents

PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

Info

Publication number
EP2571361A4
EP2571361A4 EP11783985.2A EP11783985A EP2571361A4 EP 2571361 A4 EP2571361 A4 EP 2571361A4 EP 11783985 A EP11783985 A EP 11783985A EP 2571361 A4 EP2571361 A4 EP 2571361A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
pyrazolopyrimidine compounds
pyrazolopyrimidine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11783985.2A
Other languages
German (de)
French (fr)
Other versions
EP2571361A1 (en
Inventor
Xiaodong Wang
Jing Liu
Chao Yang
Weihe Zhang
Stephen Frye
Dmitri Kireev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of EP2571361A1 publication Critical patent/EP2571361A1/en
Publication of EP2571361A4 publication Critical patent/EP2571361A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11783985.2A 2010-05-19 2011-05-12 PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER Withdrawn EP2571361A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34624110P 2010-05-19 2010-05-19
US37472910P 2010-08-18 2010-08-18
PCT/US2011/036215 WO2011146313A1 (en) 2010-05-19 2011-05-12 Pyrazolopyrimidine compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
EP2571361A1 EP2571361A1 (en) 2013-03-27
EP2571361A4 true EP2571361A4 (en) 2013-11-13

Family

ID=44991992

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11783985.2A Withdrawn EP2571361A4 (en) 2010-05-19 2011-05-12 PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

Country Status (3)

Country Link
US (2) US9290499B2 (en)
EP (1) EP2571361A4 (en)
WO (1) WO2011146313A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
MX2014004086A (en) * 2011-10-03 2014-09-22 Univ North Carolina Pyrrolopyrimidine compounds for the treatment of cancer.
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
WO2013177168A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2014018535A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
CN104098574A (en) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 Azetidine substituted pyrimidine compounds and use thereof
WO2014200682A1 (en) * 2013-05-24 2014-12-18 The Scripps Research Institute Bidentate-binding modulators of lrrk2 and jnk kinases
WO2015157127A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
EP4321513A3 (en) 2016-03-28 2024-05-08 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
JP2020502062A (en) 2016-11-17 2020-01-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Alkylpyrrolopyrimidine analogs and methods of making and using same
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
WO2019222509A1 (en) * 2018-05-16 2019-11-21 The University Of North Carolina At Chapel Hill Pyrazolopyrimidines as mertk inhibitors and their application in cancer treatment
DK3813800T3 (en) 2018-06-29 2025-06-02 Incyte Corp FORMULATIONS OF AN AXL/MER INHIBITOR
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN120712270A (en) * 2023-01-27 2025-09-26 北卡罗来纳大学教堂山分校 TYRO3 selective inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029209A2 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
WO2007134828A1 (en) * 2006-05-23 2007-11-29 Novartis Ag Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
DE10239042A1 (en) 2002-08-21 2004-03-04 Schering Ag New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
CA2527496C (en) * 2003-05-28 2012-08-14 Francesco Bondavalli 4-substituted derivatives of pyrazolo [3,4-d] pyrimidine and pyrrolo [2,3-d] pyrimidine and uses thereof
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP2260849A1 (en) 2004-01-21 2010-12-15 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
DK1713806T3 (en) 2004-02-14 2013-08-05 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
EP1749827A4 (en) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd Anti-tumor agent
CA2562244A1 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ATE520680T1 (en) 2004-09-30 2011-09-15 Tibotec Pharm Ltd HIV-INHIBITING 5-HETEROCYCLYLPYRIMIDINES
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
WO2007032445A1 (en) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitors
WO2007035963A2 (en) 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CA2624826A1 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
EA017812B1 (en) 2005-12-08 2013-03-29 Медарекс, Инк. Isolated monoclonal antibody or antigen-binding portion thereof that binds to human protein tyrosine kinase 7 (ptk7) and use thereof
US20080299113A1 (en) 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
EP1803723A1 (en) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer
AU2007233737B2 (en) 2006-03-30 2012-11-29 Janssen Sciences Ireland Uc HIV inhibiting 5-amido substituted pyrimidines
JP2009535393A (en) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク Substituted 2-amino fused heterocyclic compounds
JO3235B1 (en) 2006-05-26 2018-03-08 Astex Therapeutics Ltd Pyrrolopyrimidine compounds and their uses
CA2680122A1 (en) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
SI2212297T1 (en) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
US20100137313A1 (en) 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
JP5883384B2 (en) 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー How to regulate immune function
KR20120093867A (en) 2009-09-10 2012-08-23 아이알엠 엘엘씨 Ether derivatives of bicyclic heteroaryls
WO2011065800A2 (en) 2009-11-30 2011-06-03 주식회사 오스코텍 Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (en) 2010-10-22 2014-01-16 Astellas Pharma Inc Arylamino heterocyclic carboxamide compound
EP2640392B1 (en) 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
MX2014004086A (en) 2011-10-03 2014-09-22 Univ North Carolina Pyrrolopyrimidine compounds for the treatment of cancer.
US20160015808A1 (en) 2012-02-21 2016-01-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
MX358311B (en) 2012-04-17 2018-08-14 Fujifilm Corp HETEROCICLIC COMPOUND CONTAINING NITROGEN OR SALT OF THE SAME.
IN2012CH01573A (en) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
WO2013177168A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029209A2 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
WO2007134828A1 (en) * 2006-05-23 2007-11-29 Novartis Ag Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALY EL-SAIED A ET AL: "Heteroannelations with o-amino aldehyde and o-amino cyano of some pyrazole derivatives", AFINIDAD, BARCELONA, ES, vol. 61, no. 514, 1 January 2004 (2004-01-01), pages 510 - 515, XP009173060, ISSN: 0001-9704 *
See also references of WO2011146313A1 *

Also Published As

Publication number Publication date
WO2011146313A1 (en) 2011-11-24
US20130059836A1 (en) 2013-03-07
US9744172B2 (en) 2017-08-29
US20160279132A1 (en) 2016-09-29
EP2571361A1 (en) 2013-03-27
US9290499B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
EP2571361A4 (en) PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2763988A4 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2542081A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
EP2909211A4 (en) PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2482849A4 (en) COMBINED IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
EP2632452A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2852579A4 (en) PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2836482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2714081A4 (en) METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF CANCER
HUE047198T2 (en) Phytocannabinoids for the treatment of breast cancer
EP2830661A4 (en) DIAGNOSTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
PL3296319T3 (en) Methods of treating cancer of the colon
EP2568999A4 (en) ACTH FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2521913A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2635286A4 (en) METHODS OF TREATING CANCER
EP2544692A4 (en) USE OF TIGECYCLINE FOR THE TREATMENT OF CANCER
EP2830633A4 (en) COMBINED THERAPY FOR THE TREATMENT OF CANCER
EP2776042A4 (en) DRUG POLYTHERAPY FOR THE TREATMENT OF SOLID TUMORS
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
EP2837381A4 (en) USE OF AGENTS MODIFYING THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER
EP2773774A4 (en) BIOMARKERS FOR THE TREATMENT OF TSLP
EP2583691A4 (en) AGENT FOR THE TREATMENT OF RENAL FIBROSIS
EP2905027A4 (en) USE OF MYCOBACTERIUM BRUMAE FOR THE TREATMENT OF BLADDER CANCER

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20131015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 487/04 20060101ALI20131009BHEP

Ipc: A61K 31/519 20060101AFI20131009BHEP

Ipc: A61P 35/00 20060101ALI20131009BHEP

17Q First examination report despatched

Effective date: 20160615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161026